Forefront: Medicare Price Negotiation: The Example Of Ibrutinib
 â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â
Problems viewing this email?
View Message In Browser
<[link removed]>
Tuesday, May 2, 2023 | The Latest Research, Commentary, And News From
Health Affairs
Dear John,
We've announced several new events for May, including a Policy Spotlight
with Dawn O'Connell
<[link removed]>,
assistant secretary for preparedness and response, US Department of
Health and Human Services. Take a look at what else is upcoming this
month
<[link removed]>.
Financial Incentives And Biosimilar Uptake
[link removed]
Under the 340B Drug Pricing Program, eligible hospitals receive
substantial discounts on drug purchases, creating opportunities for them
to earn higher profits from higher-cost discounted drugs than from
lower-cost undiscounted drugs.
By analyzing the administration of two high-volume biologics versus that
of their biosimilar competitors
<[link removed]>,
Amelia Bond and coauthors estimate that 340B program eligibility is
associated with a 66 percent reduction in biosimilar use relative to the
mean.
The 340B program is also associated with "more hospital-based
administrations of and revenues from biologic medications overall."
"Our findings point to the 340B program as one driver of provider
variation in uptake of biosimilars," the authors conclude. "Given the
large proportion of hospitals participating in the 340B program, it
could be a factor that has meaningfully reduced overall biosimilar use
in the US."
Read More
<[link removed]>
Want to learn more about this research? Amelia Bond joined us on A
Health Podyssey today to discuss the paper's findings in greater detail.
Listen here
<[link removed]>.
Elsewhere At Health Affairs
Today in Forefront, Adam J. N. Raymakers and coauthors examine how
Medicare price negotiation works in practice
<[link removed]>
by looking at the specific case of the drug Ibrutinib (Imbruvica).
Zoey Chopra and A. Mark Fendrick consider the clinical implications of
the Braidwood ruling
<[link removed]>
and how it impacts coverage of preventive services.
Read more on Forefront
<[link removed]>
and learn more about how you can contribute
<[link removed]>
to the publication.
Â
[link removed]
Amelia Bond on 340B's Influence On Biosimilars
Health Affairs Editor-in-Chief Alan Weil interviews Amelia Bond from
Weill Cornell Medical College on her paper exploring whether
participation in the 340B drug program influences biosimilar uptake.
Listen Here
<[link removed]>
Â
Daily Digest
The Role Of Financial Incentives In Biosimilar Uptake In Medicare:
Evidence From The 340B Program
<[link removed]>
Amelia M. Bond et al.
Medicare Price Negotiation: The Example Of Ibrutinib
<[link removed]>
Adam J. N. Raymakers et al.
Clinical Implications Of The Braidwood Ruling: Use Of Pre-ACA Task Force
Recommendations
<[link removed]>
Zoey Chopra and A. Mark Fendrick
[link removed]
[link removed]
Â
[link removed]
Â
[link removed]
Â
[link removed]
Â
mailto:
[email protected]
About Health Affairs
Health Affairs is the leading peer-reviewed journal
<[link removed]> at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org <healthaffairs.org>, Health Affairs Today
<[link removed]>, and Health Affairs Sunday
Update <[link removed]>. Â
Project HOPE <[link removed]> is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
Privacy Policy <[link removed]>
To unsubscribe from this email, update your email preferences here
<[link removed]>.
_________________
Sent to
[email protected]
Unsubscribe:
[link removed]
Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
